基于路径的阿尔茨海默病多基因风险突出显示了认知衰退中的免疫基因
Emilija Romic1, Ida Karlsson2, Nina Karalija1
1Department of Medical and Translational Biology Umeå University, Johan Bures väg 12, 901 87 Umeå Sweden.
Alzheimer's & dementia (New York, N. Y.)
|February 11, 2026
概括
基于路径的多基因风险评分 (p-PRS) 提供了对阿尔茨海默氏症 (AD) 遗传学的见解. 免疫性p-PRS强烈预测认知衰退和痴呆风险,而粉样性p-PRS影响AD风险.
科学领域:
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种遗传复杂的疾病,其变异影响疾病机制.
- 基于路径的多基因风险评分 (p-PRS) 分析影响认知衰退的基因组.
- p-PRS可能有助于区分正常衰老和临床前痴呆症.
研究的目的:
- 研究AD加权的p-PRS在痴呆风险和认知衰退中的不同作用.
- 为了将特定途径的PRS与全基因组的PRS进行比较,用于预测痴呆和认知变化.
- 探索基因分析对痴呆症精准医学的潜力.
主要方法:
- 从贝图拉研究中分析了1,737名参与者.
- 针对免疫,,胆固醇,蛋白脂和粉样蛋白通路的AD加权p-PRS的计算.
- 关联测试与所有原因,AD和血管痴呆 (VD) 风险以及使用线性混合效应模型的认知衰退.
主要成果:
- 免疫p-PRS和全基因组PRS显著预测了所有原因的痴呆风险.
- 免疫性p-PRS与认知衰退的关联比全基因组PRS更强,特别是在非痴呆症患者中.
- 在痴呆症和非痴呆症参与者中,粉样蛋白p-PRS表明加速衰老的影响,而蛋白质脂质p-PRS显示在静脉疾病风险中发挥了潜在的作用.
结论:
- 以AD为权重的p-PRS在痴呆风险和认知衰退中发挥着独特的作用.
- 免疫性p-PRS在很大程度上与年龄相关的认知衰退和痴呆风险有关.
- 氨基酸p-PRS与AD风险和临床前衰退有关,而蛋白质脂质p-PRS可能会影响静脉疾病风险,支持个性化医学的遗传特征.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.4K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
20.2K
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:28Human Genetics
2.0K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
2.0K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35